The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
3 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $672,575 in first-year total cost, median $224,288.
Most frequent study sections
- Special Emphasis Panel[ZAR1 CHW (M1)]3
Most frequent institutions
- BIOSTRATEGIES, LC1
- EXICURE, INC.1
- SCYNEXIS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis1R43AR066387-01 | GILJOHANN, DAVID A. | EXICURE, INC., IL | $224,935 | ZAR1 |
| 2014 | Evaluation of Novel Cyclophilin D Inhibitors for Mitochondrial Disease Therapy1R43AR066393-01 | SLUDER, ANN E | SCYNEXIS, INC., NJ | $224,288 | ZAR1 |
| 2014 | Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta1R43AR066388-01 | CRAMER, CAROLE L.MORELLO, ROYRADIN, DAVID | BIOSTRATEGIES, LC, AR | $223,352 | ZAR1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.